NMN vs NR: which NAD+ precursor has better evidence?
Comparing bioavailability, clinical trial data, and cost-effectiveness of the two main NAD+ boosters.
The core question
Both NMN and NR raise NAD+ levels. Both have published human trials. Both are commercially available. So which one should you take?
The honest answer: the data does not clearly favor one over the other for human health outcomes. But the details matter if you are trying to make an informed decision.
Bioavailability differences
NR must convert to NMN before becoming NAD+. This extra step led some researchers to hypothesize that NMN might be more efficient. However, recent studies have complicated this picture.
NMN was long thought to require conversion to NR to cross cell membranes, then reconversion back to NMN inside the cell. The discovery of the Slc12a8 transporter in 2019 suggested NMN might enter cells directly, but this finding remains contested.
In practical terms, both precursors raise blood NAD+ levels by similar magnitudes at comparable doses in published human trials.
Head-to-head trial data
As of mid-2026, no large published trial has directly compared NMN and NR in the same study population with the same endpoints. Most comparisons are cross-study, which introduces confounders (different populations, different labs, different measurement methods).
Cost comparison
NR has been available longer and has more brand competition, which has driven prices down. NMN prices have dropped significantly since 2023 but remain slightly higher on average.
At equivalent doses, expect to pay roughly $40 to $80 per month for either, depending on the brand and source.
The practical recommendation
Choose based on price, availability, and personal tolerance rather than expecting a meaningful efficacy difference. The evidence does not support paying a premium for one over the other.